Access the full text.
Sign up today, get DeepDyve free for 14 days.
N. Galili, Richard Davis, W. Fredericks, Sunil Mukhopadhyay, F. Rauscher, B. Emanuel, G. Rovera, F. Barr (1993)
Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcomaNature Genetics, 5
J. Bennicelli, William Fredericks, Robert Wilson, Frank Rauscher, F. Barr (1995)
Wild type PAX3 protein and the PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma contain potent, structurally distinct transcriptional activation domains.Oncogene, 11 1
R. George, T. Sanda, M. Hanna, S. Fröhling, William Ii, Jianming Zhang, Yebin Ahn, Wenjun Zhou, W. London, Patrick McGrady, L. Xue, S. Zozulya, V. Gregor, Thomas Webb, N. Gray, D. Gilliland, L. Diller, H. Greulich, S. Morris, M. Meyerson, A. Look (2008)
Activating mutations in ALK provide a therapeutic target in neuroblastomaNature, 455
Seng Tang, Luan Nguyen, R. Sparidans, E. Wagenaar, J. Beijnen, A. Schinkel (2014)
Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P‐glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridarInternational Journal of Cancer, 134
S. Xia, J. Pressey, F. Barr (2002)
Molecular Pathogenesis of RhabdomyosarcomaCancer Biology & Therapy, 1
A. Marshall, G. Grosveld (2012)
Alveolar rhabdomyosarcoma – The molecular drivers of PAX3/7-FOXO1-induced tumorigenesisSkeletal Muscle, 2
J. Hyatt, L. Tsurkan, M. Wierdl, C. Edwards, M. Danks, P. Potter (2006)
Intracellular inhibition of carboxylesterases by benzil: modulation of CPT-11 cytotoxicityMolecular Cancer Therapeutics, 5
Johannes Schulte, S. Schulte, Lukas Heukamp, Kathy Astrahantseff, Harald Stephan, Matthias Fischer, Alexander Schramm, Angelika Eggert (2013)
Targeted Therapy for Neuroblastoma: ALK InhibitorsKlinische Pädiatrie, 225
J. Proffitt (1985)
DNase I-hypersensitive sites in the galactose gene cluster of Saccharomyces cerevisiaeMolecular and Cellular Biology, 5
E. Douglass, M. Valentine, E. Etcubanas, D. Parham, B. Webber, P. Houghton, J. Houghton, A. Green (1987)
A specific chromosomal abnormality in rhabdomyosarcoma.Cytogenetics and cell genetics, 45 3-4
J. Gaal, U. Flucke, M. Roeffen, E. Bont, S. Sleijfer, A. Mavinkurve-Groothuis, A. Suurmeijer, W. Graaf, Y. Versleijen-Jonkers (2012)
Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 3
Elizabeth Stewart, Sara Federico, Asa Karlstrom, A. Shelat, A. Sablauer, A. Pappo, M. Dyer (2016)
The Childhood Solid Tumor Network: A new resource for the developmental biology and oncology research communities.Developmental biology, 411 2
Chun-hong Zhu, V. Mouly, R. Cooper, K. Mamchaoui, A. Bigot, J. Shay, J. Santo, G. Butler-Browne, W. Wright (2007)
Cellular senescence in human myoblasts is overcome by human telomerase reverse transcriptase and cyclin‐dependent kinase 4: consequences in aging muscle and therapeutic strategies for muscular dystrophiesAging Cell, 6
W. Fredericks, N. Galili, Sunil Mukhopadhyay, G. Rovera, J. Bennicelli, F. Barr, F. Rauscher (1995)
The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3Molecular and Cellular Biology, 15
Rongshi Li, Stephan Morris (2008)
Development of anaplastic lymphoma kinase (ALK) small‐molecule inhibitors for cancer therapyMedicinal Research Reviews, 28
P. Bonvini, A. Zin, R. Alaggio, B. Pawel, G. Bisogno, Angelo Rosolen (2013)
High ALK mRNA expression has a negative prognostic significance in rhabdomyosarcomaBritish Journal of Cancer, 109
Diana Corao, J. Biegel, C. Coffin, F. Barr, L. Wainwright, L. Ernst, J. Choi, Paul Zhang, B. Pawel (2009)
ALK Expression in Rhabdomyosarcomas: Correlation with Histologic Subtype and Fusion StatusPediatric and Developmental Pathology, 12
K. Pillay, D. Govender, R. Chetty (2002)
ALK protein expression in rhabdomyosarcomas.Histopathology, 41 5
Y. Choi, K. Takeuchi, M. Soda, K. Inamura, Yuki Togashi, S. Hatano, Munehiro Enomoto, T. Hamada, H. Haruta, Hideki Watanabe, K. Kurashina, Hisashi Hatanaka, Toshihide Ueno, S. Takada, Y. Yamashita, Y. Sugiyama, Y. Ishikawa, H. Mano (2008)
Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.Cancer research, 68 13
L. Lamant, K. Pulford, D. Bischof, S. Morris, D. Mason, G. Delsol, B. Mariamé (2000)
Expression of the ALK tyrosine kinase gene in neuroblastoma.The American journal of pathology, 156 5
Malcolm Smith, N. Seibel, S. Altekruse, L. Ries, Danielle Melbert, M. O'Leary, F. Smith, G. Reaman (2010)
Outcomes for children and adolescents with cancer: challenges for the twenty-first century.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 15
D. Gerber, J. Minna (2010)
ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time.Cancer cell, 18 6
Yuyan Chen, J. Takita, Y. Choi, Motohiro Kato, M. Ohira, M. Sanada, Lili Wang, M. Soda, A. Kikuchi, T. Igarashi, A. Nakagawara, Y. Hayashi, H. Mano, S. Ogawa (2008)
Oncogenic mutations of ALK kinase in neuroblastomaNature, 455
A. Yoshida, T. Shibata, S. Wakai, T. Ushiku, K. Tsuta, M. Fukayama, A. Makimoto, K. Furuta, H. Tsuda (2013)
Anaplastic lymphoma kinase status in rhabdomyosarcomasModern Pathology, 26
M. Davare, A. Saborowski, C. Eide, C. Tognon, Rebecca Smith, J. Elferich, A. Agarwal, J. Tyner, U. Shinde, S. Lowe, B. Druker (2013)
Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteinsProceedings of the National Academy of Sciences, 110
Richard Davis, C. D’Cruz, M. Lovell, J. Biegel, F. Barr (1994)
Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma.Cancer research, 54 11
J. Biegel, L. Nycum, V. Valentine, F. Barr, D. Shapiro (1995)
Detection of the t(2;13)(q35;q14) and PAX3‐FKHR fusion in alveolar rhabdomyosarcoma by fluorescence in situ hybridizationGenes, 12
Xiang Chen, Elizabeth Stewart, A. Shelat, Chunxu Qu, A. Bahrami, M. Hatley, Gang Wu, Cori Bradley, Justina McEvoy, A. Pappo, S. Spunt, M. Valentine, V. Valentine, Fred Krafcik, Walter Lang, M. Wierdl, Lyudmila Tsurkan, Viktor Tolleman, Sara Federico, C. Morton, Charles Lu, L. Ding, J. Easton, Michael Rusch, Panduka Nagahawatte, Jianmin Wang, Matthew Parker, Lei Wei, Erin Hedlund, D. Finkelstein, M. Edmonson, S. Shurtleff, Kristy Boggs, H. Mulder, D. Yergeau, S. Skapek, D. Hawkins, N. Ramirez, P. Potter, J. Sandoval, A. Davidoff, E. Mardis, R. Wilson, Jinghui Zhang, J. Downing, M. Dyer (2013)
Targeting oxidative stress in embryonal rhabdomyosarcoma.Cancer cell, 24 6
Elizabeth Stewart, A. Shelat, Cori Bradley, Xiang Chen, Sara Federico, Suresh Thiagarajan, A. Shirinifard, A. Bahrami, A. Pappo, Chunxu Qu, D. Finkelstein, A. Sablauer, M. Dyer (2015)
Development and characterization of a human orthotopic neuroblastoma xenograftDevelopmental biology, 407
JH Schulte, S Schulte, LC Heukamp, K Astrahantseff, H Stephan, M Fischer, A Schramm, A Eggert (2013)
Targeted therapy for neuroblastoma: ALK inhibitorsKlin Padiatr, 225
K. Livak, Thomas Schmittgen (2001)
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.Methods, 25 4
B. Hazelton, J. Houghton, D. Parham, E. Douglass, P. Torrance, H. Holt, P. Houghton (1987)
Characterization of cell lines derived from xenografts of childhood rhabdomyosarcoma.Cancer research, 47 16
S. Rodig, G. Shapiro (2010)
Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.Current opinion in investigational drugs, 11 12
F. Barr, J. Chatten, C. D’Cruz, Albert Wilson, L. Nauta, L. Nycum, J. Biegel, R. Womer (1995)
Molecular assays for chromosomal translocations in the diagnosis of pediatric soft tissue sarcomas.JAMA, 273 7
DA Corao, JA Biegel, CM Coffin, FG Barr, LM Wainwright, LM Ernst, JK Choi, PJ Zhang, BR Pawel (2009)
ALK expression in rhabdomyosarcomas: correlation with histologic subtype and fusion status. Pediatric and developmental pathologyPediatr Dev Pathol, 12
Purpose The anaplastic lymphoma kinase (ALK) has been demonstrated to be a valid clinical target in diseases such as anaplastic large cell lymphoma and non-small cell lung cancer. Recent studies have indicated that ALK is overexpressed in pediatric rhabdomyosarcoma (RMS) and hence we hypothesized that this kinase may be a suitable candidate for therapeutic intervention in this tumor. Methods We evaluated the expression of ALK in a panel of pediatric RMS cell lines and patient-derived xenografts (PDX), and sensitivity to ALK inhibitors was assessed both in vitro and in vivo. Results Essentially, all RMS lines were sensitive to crizotinib, NVP-TAE684 or LDK-378 in vitro, and molecular analyses demonstrated inhibition of RMS cell proliferation following siRNA-mediated reduction of ALK expression. However, in vivo PDX studies using ALK kinase inhibitors demonstrated no antitumor activity when used as single agents or when combined with standard of care therapy (vincristine, actinomycin D and cyclophosphamide). More alarmingly, however, crizotinib actually accelerated the growth of these tumors in vivo. Conclusions While ALK appears to be a relevant target in RMS in vitro, targeting this kinase in vivo yields no therapeutic efficacy, warranting extreme caution when considering the use of these agents in pediatric RMS patients. Keywords Rhabdomyosarcoma · ALK · Patient-derived xenografts · ALK inhibitors ·
Cancer Chemotherapy and Pharmacology – Springer Journals
Published: May 31, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.